Informed by nature
and guided by science
Informed
by nature
and guided
by science
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Bringing together leaders in the business of medicine and science
Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Psyence Group’s RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana’s Shallow Continental Shelf
Psyence Group Inc. (CSE: PSYG) has announced that its proposed reverse takeover target, GoldCoast Resource Corp., has been granted ten contiguous offshore reconnaissance licenses by Ghana’s Minerals Commission. Covering roughly 10,000 square kilometres along Ghana’s western offshore continental shelf, the licenses allow GoldCoast to begin early-stage reconnaissance work under Ghanaian mining regulations, with an initial 12-month term and renewal options. Psyence and GoldCoast also confirmed they are continuing to progress their proposed transaction, which remains subject to customary regulatory, technical disclosure, financial, shareholder, and Canadian Securities Exchange approval requirements.
Psyence Group Inc. Enters Into Amalgamation Agreement With Goldcoast Resource Corp.
Psyence Group Inc. has entered into a definitive amalgamation agreement (the “Agreement”) dated November 21, 2025 with GoldCoast Resource Corp. (“GoldCoast”) and Psyence Therapeutics Corp., a wholly owned subsidiary of Psyence (“Psyence Subco”).
Psyence Group Inc. Announces RSU Grants
Psyence Group Inc. (CSE: PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU") to certain executives, officers, directors and consultants of the Company pursuant to the Company’s Amended and Restated Restricted Share Unit Plan, of which one third vests six months after the grant date, another one third after twelve months and the remaining balance after eighteen months.
